The KMT2A recombinome of acute leukemias in 2023Claus Meyer, Emmanuelle Clappier, Nicola C. Venn et al.|Leukemia|2023Cited by 214
Genetic alterations and MRD refine risk assessment for <i>KMT2A</i>-rearranged B-cell precursor ALL in adults: a GRAALL studyRathana Kim, Emmanuelle Clappier, Hugo Bergugnat et al.|Blood|2023Cited by 29
137 | IBRUTINIB ADDED TO MCL TREATMENT HAS STRONG IMPACT ON MRD RESPONSE AND DISEASE KINETICS: RESULTS FROM THE TRIANGLE TRIALMouhamad Khouja, Christiane Pott, Vindi Jurinović et al.|Hematological Oncology|2025Cited by 1